Reviewer’s report

Title: T-SPOT.TB responses during treatment of pulmonary tuberculosis

Version: 2 Date: 13 January 2009

Reviewer: Edward Graviss

Reviewer's report:

1) No major compulsory revisions
2) No minor essential revisions
3) Discretionary revisions - As the site of extrapulmonary disease has not been captured by the original CRF and data set, a short clarification in the methods sections might be warranted.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received research support from both Oxford Immunotec, Ltd the manufacturer of the T-SPOT assay and Cellestis, Ltd the manufacturer of QuantIFERON. Both products are the only US FDA approved IGRA currently on the market.